Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis;Wirkmechanismen von Diclofenac 3 %/Hyaluronsäure 2,5 % bei der Behandlung aktinischer Keratosen

JDDG - Journal of the German Society of Dermatology

Volumn 9, Issue 12, 2011, Pages 1011-1017

  Maltusch, Adrienne ^a   Röwert Huber, Joachim ^a   Matthies, Carmen ^b   Lange Asschenfeldt, Susanne ^a   Stockfleth, Eggert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Almirall Hermal GmbH   (Germany)

Author keywords

actinic keratosis; angiogenesis; apoptosis; diclofenac; immunohistochemistry; inflammation

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; DICLOFENAC; HYALURONIC ACID; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53;

ACTINIC KERATOSIS; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN INFLAMMATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DICLOFENAC; DRUG COMBINATIONS; FEMALE; HUMANS; HYALURONIC ACID; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 81255189130     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2011.07700.x     Document Type: Article

References (32)

1. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, Sterry W, Stockfleth E,. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156 Suppl 3: 8-12. Erratum in: Br J Dermatol 2007; 157: 431.
2. Callen JP, Bickers DR, Moy RL,. Actinic keratoses. LJ Am Acad Dermatol 1997; 36: 650-3.
3. Hruza LL, Pentland AP,. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993; 100: 35S-41S.
4. Sluyter R, Halliday GM,. Infiltration by inflammatory cells required for solar-simulated ultraviolet radiation enhancement of skin tumor growth. Cancer Immunol Immunother 2001; 50: 151-6.
5. Halliday GM, Bestak R, Yuen KS, Cavanagh LL, Barnetson RS,. UVA-induced immunosuppression. Mutat Res 1998; 422: 139-45.
6. Chipuk JE, Green DR,. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008; 18: 157-64.
7. Wang D, Dubois RN,. Prostaglandins and cancer. Gut 2006; 55: 115-22.
8. Moore AR, Willoughby DA,. Hya-luronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995; 17: 153-6.
9. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y,. Topical treatment of actinic keratoses with 3.0 % diclofenac in 2.5 % hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
10. Wolf JE Jr, Taylor JR, Tschen E, Kang S,. Topical 3.0 % diclofenac in 2.5 % hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
11. Gebauer K, Brown P, Varigos G,. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40-3.
12. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN,. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16. Erratum in: Cell 1998; 94: following 271.
13. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN,. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005; 65: 1822-9.
14. Tsujii M, DuBois RN,. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostag-landin endoperoxide synthase 2. Cell 1995; 83: 493-501.
15. Fecker LF, Stockfleth E, Braun FK, Rodust PM, Schwarz C, Köhler A, Leverkus M, Eberle J,. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol 2010; 130: 2098-109.
16. Guesdon JL, Ternynck T, Avrameas S,. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979; 27: 1131-9.
17. Giorno R,. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 1984; 2: 161-6.
18. Moy RL,. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 8-10.
19. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM,. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 2000; 62: 367-84.
20. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ,. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med 1997; 216: 201-10.
21. Black AK, Greaves MW, Hensby CN, Plummer NA,. Increased prostaglandins E2 and F2alpha in human skin at 6 and 24 h after ultraviolet B irradiation (290- 320 nm). Br J Clin Pharmacol 1978; 5: 431-6.
22. Seo JY, Kim EK, Lee SH, Park KC, Kim KH, Eun HC, Chung JH,. Enhanced expression of cylooxygenase-2 by UV in aged human skin in vivo. Mech Ageing Dev 2003; 124: 903-10.
23. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP,. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9.
24. Dirschka T, Bierhoff E, Pflugfelder A, Garbe C,. Topical 3.0 % diclofenac in 2.5 % hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol 2010; 24: 258-63.
25. Vane JR, Botting RM,. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10.
26. Goodwin JS, Ceuppens J,. Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3: 295-315.
27. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE,. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
28. Fecker L F, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J,. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007; 156 (Suppl 3): 25-33.
29. Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E,. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res 2010; 704: 12-20.
30. da Silva TA, Coelho G, Lorenzetti Bocca A, Figueiredo Cavalcante Neto F,. Expression of apoptotic, cell proliferation regulatory, and structural proteins in actinic keratosis and their association with dermal elastosis. J Cutan Pathol 2007; 34: 315-23.
31. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS,. Inhibition of angiogenesis by nonstero-idal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
32. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K,. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.